Joshi Asim, Ghosh Abantika, Ramachandran Venkataramanan, Kuriakose Moni, Prabhash Kumar, Kumar Prashant
Karkinos Healthcare Pvt Ltd, 21st Floor, Rupa Renaissance, D33, Turbhe MIDC Road, Navi Mumbai, Maharashtra 400705 India.
Karkinos Foundation, Mumbai, Maharashtra 400086 India.
J Maxillofac Oral Surg. 2024 Aug;23(4):772-782. doi: 10.1007/s12663-024-02254-w. Epub 2024 Jun 17.
Oral cancer is a significant global health concern, with high morbidity and mortality rates, particularly in regions with prevalent tobacco usage such as Asia. Majority of oral cancers are detected at an advanced stage resulting in poor survival outcomes. Moreover, the treatment modalities of oral cancers have remained constant with surgery and concurrent chemoradiotherapy being mainstays of the treatment. This review provides a significant progress made in understanding the molecular landscape of oral cancers and the evolution of therapeutic strategies toward precision medicine.
A comprehensive literature review was conducted to gather recent studies on the molecular landscape of oral cancers, genomic insights, and clinical trials.
Firstly, genomic insights into oral cancers, including key driver mutations and copy number alterations, are discussed in the context of personalized medicine approaches. Subsequently, advancements in therapeutic strategies, particularly focusing on clinical trials investigating immunotherapy and targeted agents, are highlighted.
Despite promising results, challenges persist in identifying reliable biomarkers for treatment response and resistance. Continued research efforts are warranted to validate biomarkers and optimize therapeutic interventions, with the goal of enhancing patient outcomes and reducing the global burden of oral cancer.
口腔癌是一个重大的全球健康问题,发病率和死亡率都很高,尤其是在亚洲等烟草使用普遍的地区。大多数口腔癌在晚期才被发现,导致生存结果不佳。此外,口腔癌的治疗方式一直没有改变,手术和同步放化疗仍然是主要的治疗方法。本综述阐述了在了解口腔癌分子格局以及治疗策略向精准医学发展方面取得的重大进展。
进行了全面的文献综述,以收集有关口腔癌分子格局、基因组见解和临床试验的最新研究。
首先,在个性化医疗方法的背景下讨论了口腔癌的基因组见解,包括关键驱动突变和拷贝数改变。随后,重点介绍了治疗策略的进展,特别是针对研究免疫疗法和靶向药物的临床试验。
尽管取得了有前景的结果,但在确定治疗反应和耐药性的可靠生物标志物方面仍存在挑战。需要持续的研究努力来验证生物标志物并优化治疗干预措施,目标是改善患者预后并减轻全球口腔癌负担。